Attovia Therapeutics raises capital in 17 dollar Nasdaq IPO debut
Biopharmaceutical firm Attovia Therapeutics listed on the Nasdaq stock exchange pricing its initial public offering at 17 00 dollars per share to expand clinical development
We haven't written up this one. Vietnam Investment Review has the full story — the link below goes straight to it.